company background image
6734

iXensor TPEX:6734 Stock Report

Last Price

NT$11.00

Market Cap

NT$603.2m

7D

-0.9%

1Y

-36.8%

Updated

07 Aug, 2022

Data

Company Financials
6734 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

6734 Stock Overview

iXensor Co., Ltd. provides technology platform that turns smartphones into in vitro diagnostic devices through its smart color sensing technology for connected healthcare.

iXensor Competitors

Price History & Performance

Summary of all time highs, changes and price drops for iXensor
Historical stock prices
Current Share PriceNT$11.00
52 Week HighNT$26.25
52 Week LowNT$10.40
Beta0.63
1 Month Change-7.95%
3 Month Change-32.52%
1 Year Change-36.78%
3 Year Change-60.43%
5 Year Changen/a
Change since IPO-68.02%

Recent News & Updates

Mar 24
Will iXensor (GTSM:6734) Spend Its Cash Wisely?

Will iXensor (GTSM:6734) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Dec 10
Is iXensor (GTSM:6734) In A Good Position To Invest In Growth?

Is iXensor (GTSM:6734) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Shareholder Returns

6734TW Medical EquipmentTW Market
7D-0.9%-3.4%0.1%
1Y-36.8%-8.2%-14.4%

Return vs Industry: 6734 underperformed the TW Medical Equipment industry which returned -8.2% over the past year.

Return vs Market: 6734 underperformed the TW Market which returned -14.4% over the past year.

Price Volatility

Is 6734's price volatile compared to industry and market?
6734 volatility
6734 Average Weekly Movement8.6%
Medical Equipment Industry Average Movement5.2%
Market Average Movement5.1%
10% most volatile stocks in TW Market8.4%
10% least volatile stocks in TW Market2.5%

Stable Share Price: 6734 is more volatile than 90% of TW stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: 6734's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of TW stocks.

About the Company

FoundedEmployeesCEOWebsite
2012n/aCarson Chenhttps://www.ixensor.com

iXensor Co., Ltd. provides technology platform that turns smartphones into in vitro diagnostic devices through its smart color sensing technology for connected healthcare. The company’s PixoTest technology uses the lighting and image sensing module of the smartphone to detect the color change reaction on the immunoassay or colorimetric strip. It offers PixoTest Blood Glucose Monitoring System and PixoTest POCT System for chronic diseases management; Eveline Smart Fertility System and Eveline Care Telehealth Platform for women’s health management; and PixoTest COVID-19 Rapid Antigen Test for infectious disease management, as well as PixoHealth Pass Admin app and Web portal.

iXensor Fundamentals Summary

How do iXensor's earnings and revenue compare to its market cap?
6734 fundamental statistics
Market CapNT$603.21m
Earnings (TTM)-NT$73.08m
Revenue (TTM)NT$24.79m

24.3x

P/S Ratio

-8.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
6734 income statement (TTM)
RevenueNT$24.79m
Cost of RevenueNT$20.17m
Gross ProfitNT$4.62m
Other ExpensesNT$77.70m
Earnings-NT$73.08m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-1.33
Gross Margin18.63%
Net Profit Margin-294.75%
Debt/Equity Ratio0%

How did 6734 perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is 6734 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6734?

Other financial metrics that can be useful for relative valuation.

6734 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue23.8x
Enterprise Value/EBITDA-7.7x
PEG Ration/a

Price to Sales Ratio vs Peers

How does 6734's PS Ratio compare to its peers?

6734 PS Ratio vs Peers
The above table shows the PS ratio for 6734 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average3.8x
6493 Ttbio
1.7xn/aNT$529.1m
4188 AmCad BioMed
9.6xn/aNT$878.2m
1781 Health & Life
0.9xn/aNT$666.1m
6730 Lagis Enterprise
2.9xn/aNT$1.1b
6734 iXensor
24.3xn/aNT$603.2m

Price-To-Sales vs Peers: 6734 is expensive based on its Price-To-Sales Ratio (24.3x) compared to the peer average (3.8x).


Price to Earnings Ratio vs Industry

How does 6734's PE Ratio compare vs other companies in the TW Medical Equipment Industry?

Price-To-Sales vs Industry: 6734 is expensive based on its Price-To-Sales Ratio (24.3x) compared to the TW Medical Equipment industry average (2.5x)


Price to Sales Ratio vs Fair Ratio

What is 6734's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6734 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio24.3x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 6734's Price-To-Sales Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of 6734 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 6734's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 6734's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is iXensor forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


16.4%

Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as iXensor has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Examine iXensor's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.

Past Performance

How has iXensor performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


6.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 6734 is currently unprofitable.

Growing Profit Margin: 6734 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 6734 is unprofitable, but has reduced losses over the past 5 years at a rate of 6.2% per year.

Accelerating Growth: Unable to compare 6734's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6734 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (13.7%).


Return on Equity

High ROE: 6734 has a negative Return on Equity (-128.23%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is iXensor's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: 6734's short term assets (NT$56.7M) exceed its short term liabilities (NT$16.6M).

Long Term Liabilities: 6734 has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: 6734 is debt free.

Reducing Debt: 6734 has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 6734 has sufficient cash runway for 2 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: 6734 is forecast to have sufficient cash runway for 2 months based on free cash flow estimates, but has since raised additional capital.


Discover healthy companies

Dividend

What is iXensor current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate 6734's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 6734's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 6734's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 6734's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 6734 has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Carson Chen

no data

Tenure

Dr. Carson Chen Ph.D. is Chief Executive Officer & Co-Founder of iXensor Co., Ltd. Dr. Chen is a visionary leader with strong business acumen, a proven track record of innovation success, and a solid under...


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.8%.


Top Shareholders

Company Information

iXensor Co., Ltd.'s employee growth, exchange listings and data sources


Key Information

  • Name: iXensor Co., Ltd.
  • Ticker: 6734
  • Exchange: TPEX
  • Founded: 2012
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: NT$603.206m
  • Shares outstanding: 54.84m
  • Website: https://www.ixensor.com

Location

  • iXensor Co., Ltd.
  • No.9, Aly. 2, Ln. 35
  • 6th Floor
  • Taipei
  • 11492
  • Taiwan

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/07 00:00
End of Day Share Price2022/08/05 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.